REGENXBIO Inc. (NASDAQ:RGNX) insider Kenneth T. Mills sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 21st. The shares were sold at an average price of $47.05, for a total value of $470,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
REGENXBIO opened at $47.20 on Friday, Marketbeat reports. REGENXBIO Inc. has a twelve month low of $16.30 and a twelve month high of $51.20. The company has a market cap of $1.49 billion, a P/E ratio of -19.27, a P/E/G ratio of 25.01 and a beta of -1.23.
REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $3.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.00 by $2.04. REGENXBIO had a return on equity of 23.27% and a net margin of 37.28%. The company had revenue of $132.39 million during the quarter, compared to analyst estimates of $80.00 million. equities analysts forecast that REGENXBIO Inc. will post 0.61 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of RGNX. Bayesian Capital Management LP bought a new position in REGENXBIO during the 1st quarter valued at approximately $220,000. Trexquant Investment LP bought a new position in REGENXBIO during the 1st quarter valued at approximately $233,000. Cubist Systematic Strategies LLC bought a new position in REGENXBIO during the 1st quarter valued at approximately $241,000. Element Capital Management LLC bought a new position in REGENXBIO during the 1st quarter valued at approximately $281,000. Finally, Teacher Retirement System of Texas bought a new position in REGENXBIO during the 4th quarter valued at approximately $302,000. 69.26% of the stock is owned by institutional investors.
A number of research firms have recently commented on RGNX. Zacks Investment Research upgraded REGENXBIO from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Friday, March 16th. TheStreet upgraded REGENXBIO from a “d+” rating to a “c” rating in a research note on Friday, May 11th. Raymond James set a $45.00 target price on REGENXBIO and gave the company a “buy” rating in a research note on Wednesday, April 11th. Mizuho began coverage on REGENXBIO in a research note on Monday, February 12th. They issued a “neutral” rating and a $28.00 target price for the company. Finally, BidaskClub upgraded REGENXBIO from a “hold” rating to a “buy” rating in a research note on Friday, April 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $43.25.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.